BioAdvance Capital

What they do

BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund. They invest in therapeutics, devices, diagnostics and platform technologies focused on human health. Since its first investments in 2003, BioAdvance has become one of the nation's leading investors providing pre-seed and seed-stage funding. To date they have committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies.

What they look for

BioAdvance invests strategic, milestone-driven capital in early-stage life sciences opportunities (therapeutics, medical devices, digital health, diagnostics, and research tools) in the Mid-Atlantic region to help companies reach critical de-risking milestones and attract follow-on capital.

Stage

Seed, Series A

Sectors

Healthcare

Based

Philadelphia, US